Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer: Systematic Review with Meta-Analysis

Lima, João Paulo da Silveira Nogueira; Santos, Lucas Vieira dos; Sasse, Emma Chen; Lima, Carmen Sílvia Passos; Sasse, André Deeke

doi:10.1097/jto.0b013e3181f2451c

Cited by 48 publications

(28 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent meta-analysis suggests an improvement in progression-free survival and overall survival with irinotecan plus platinum regimens compared with etoposide plus platinum regimens. 67 However, this meta-analysis was not performed using individual patient data. In addition, the relatively small absolute survival benefit must be balanced against the toxicity profile of irinotecan-based regimens.…”

Section: Chemotherapymentioning

confidence: 99%

Small Cell Lung Cancer

Kalemkerian¹,

Akerley²,

Bogner³

et al. 2013

J Natl Compr Canc Netw

355

244

View full text Add to dashboard Cite

Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

show abstract

Section: Chemotherapymentioning

confidence: 99%

Small Cell Lung Cancer

Kalemkerian¹,

Akerley²,

Bogner³

et al. 2013

J Natl Compr Canc Netw

355

244

View full text Add to dashboard Cite

show abstract

“…Neoadjuvant strategies incorporating oxaliplatin are also being developed, and thus robust predictive markers are required to optimise patient selection and maximise clinical benefit. Beyond its role in colorectal cancer, which will be the main focus of this review, there is also growing interest in the use of irinotecan in small-cell lung cancer, where there is evidence of increased efficacy over etoposide regimens (Lima et al , 2010), and a range of other tumour types including glioblastoma.…”

Section: Clinical Utility Of Topoisomerase I (Top 1) Poisonsmentioning

confidence: 99%

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets

2011

View full text Add to dashboard Cite

The topoisomerase I (Top 1) poison irinotecan is an important component of the modern treatment of colorectal cancer. By stabilising Top 1-DNA complexes, irinotecan generates Top 1-linked DNA single-strand breaks that can evolve into double-strand breaks and ultimately cause cell death. However, cancer cells may overcome cell killing by releasing the stalled topoisomerase from DNA termini, thereby reducing the efficacy of Top 1 poisons in clinics. Thus, understanding the DNA repair mechanisms involved in the repair of Top 1-mediated DNA damage provides a useful tool to identify potential biomarkers that predict response to this class of chemotherapy. Furthermore, targeting these pathways could enhance the therapeutic benefits of Top 1 poisons. In this review, we describe the cellular mechanisms and consequences of targeting Top 1 activity in cells. We summarise preclinical data and discuss the potential clinical utility of small-molecule inhibitors of the key proteins.

show abstract

“…A recent metaanalysis suggests an improvement in PFS and overall survival with irinotecan plus platinum regimens compared with etoposide plus platinum regimens. 70 However, this meta-analysis was not performed using individual patient data. In addition, the relatively small absolute survival benefit must be balanced against the toxicity profile of irinotecan-based regimens.…”

Section: Chemotherapymentioning

confidence: 99%